Management Team

James Caruso

President, CEO and Director

James Caruso

James Caruso

President, CEO and Director

Mr. Caruso was appointed Cellectar Biosciences’ President and Chief Executive Officer and a director in June 2015. A life sciences executive with 33 years of professional success with multinational and specialty pharmaceutical companies, mid-tier biotechnology and medical device start-ups, Mr. Caruso has an established track record of enhancing value through a clear focus on strategic corporate value drivers and operational excellence; fostering high performance cultures and advancing product development and commercialization programs through internal execution and corporate collaborations. He comes to Cellectar Biosciences from Hip Innovation Technology, a successful private medical device company where he was a founder and served as Executive Vice President and Chief Operating Officer. Prior to his time at Hip Innovation Technology, he was Executive Vice President and Chief Commercial Officer of Allos Therapeutics, Inc., an oncology company acquired by Spectrum Pharmaceuticals, and Senior Vice President, Sales and Marketing, at Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation. In addition, Mr. Caruso has held key leadership positions with multinational pharmaceutical companies, including Novartis, where he was Vice President of Neuroscience Specialty Sales; BASF Pharmaceuticals-Knoll, where he was Vice President of Primary Care and Specialty Sales; and 12 years at Bristol-Myers Squibb Company in senior sales and marketing roles. Mr. Caruso earned a Bachelor of Science degree in Finance from the University of Nevada. He currently serves on the Board of Directors for Hip Innovation Technology.

Chad Kolean

Chief Financial Officer

Chad Kolean

Chad Kolean

Chief Financial Officer

Mr. Kolean served as Chief Financial Officer to both Vivex Biologics, a regenerative medicine company and Titan Spine, a spinal implant med-tech company sold to Medtronic. Mr. Kolean also served as Chief Financial Officer and Treasurer for Pioneer Surgical Technology, a biologic and orthopedic implant company through its merger with RTI Surgical. Early in his career, Mr. Kolean held leadership positions of increasing responsibility at multinational companies and those within the healthcare space including Tomotherapy, Inc., Metavante Corporation, Snap On, Inc., Herman Miller, Inc., Kaydon Corporation, and Arthur Andersen, LLP. Mr. Kolean earned his Bachelor of Arts in Business Administration and Finance from Hope College and graduated Magna Cum Laude.

Jarrod Longcor

Chief Operating Officer

Jarrod Longcor

Jarrod Longcor

Chief Operating Officer

Mr. Longcor brings to Cellectar Biosciences, Inc. more than 20 years of pharmaceutical and biotech experience and was previously the Chief Business Officer for Avillion LLP. In this role, he was responsible for executing the company’s unique co-development partnership strategy. Prior to Avillion, Jarrod was the Vice President of Corporate Development for Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics) where he was responsible for identifying and concluding several critical collaborations for the company, including a major discovery collaboration with Sanofi Aventis valued over $700M. Prior to Rib-X, Mr. Longcor has held key positions in several small to midsized biotech companies where he was responsible for business development, strategic planning and operations. Jarrod holds a Bachelor of Science degree from Dickinson College, a Master of Science from Boston University School of Medicine and a Master of Business Administration from Saint Joseph’s University’s Haub School of Business.

Dr. Laurence Reilly M.D., LL.M

Interim Chief Medical Officer

Dr. Laurence Reilly M.D., LL.M

Dr. Laurence Reilly M.D., LL.M

Interim Chief Medical Officer

Dr. Reilly brings to Cellectar Biosciences Inc. more than 16 years of clinical development experience within pharma, biotech and medical devices. He previously served as Chief Scientific Officer & Vice President for Avillion LLP, a London-based clinical co-development and investment company, where he was responsible for oversight of pivotal clinical programs with partners such as Pfizer and AstraZeneca. Dr. Reilly has served in the role of Chief Strategic and Development officer for a European Medical Device & Innovations company and has provided strategic consulting and due diligence services in his private consulting practice to Life Science venture capital and private equity groups. Dr. Reilly previously served as a clinician at both Pfizer and Lundbeck and has been responsible for clinical development program design and driving development programs through to approval across Haematology/Oncology as well as a variety of other therapeutic indications. Dr. Reilly is dual-qualified in medicine and in law. He gained his medical degree from the University of Liverpool (U.K.) and his master’s degree in law from De Montford University, U.K.